Skip to main navigation Skip to search Skip to main content

Bioengineered small extracellular vesicles deliver multiple SARS‐CoV‐2 antigenic fragments and drive a broad immunological response

  • Hannah K. Jackson
  • , Heather M. Long
  • , Juan Carlos Yam‐Puc
  • , Roberta Palmulli
  • , Tracey A. Haigh
  • , Pehuén Pereyra Gerber
  • , Jin S. Lee
  • , Nicholas J. Matheson
  • , Lesley Young
  • , John Trowsdale
  • , Mathew Lo
  • , Graham S. Taylor
  • , James E. Thaventhiran
  • , James R. Edgar*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

185 Downloads (Pure)

Abstract

The COVID‐19 pandemic highlighted the clear risk that zoonotic viruses pose to global health and economies. The scientific community responded by developing several efficacious vaccines which were expedited by the global need for vaccines. The emergence of SARS‐CoV‐2 breakthrough infections highlights the need for additional vaccine modalities to provide stronger, long‐lived protective immunity. Here we report the design and preclinical testing of small extracellular vesicles (sEVs) as a multi‐subunit vaccine. Cell lines were engineered to produce sEVs containing either the SARS‐CoV‐2 Spike receptor‐binding domain, or an antigenic region from SARS‐CoV‐2 Nucleocapsid, or both in combination, and we tested their ability to evoke immune responses in vitro and in vivo. B cells incubated with bioengineered sEVs were potent activators of antigen‐specific T cell clones. Mice immunised with sEVs containing both sRBD and Nucleocapsid antigens generated sRBD‐specific IgGs, nucleocapsid‐specific IgGs, which neutralised SARS‐CoV‐2 infection. sEV‐based vaccines allow multiple antigens to be delivered simultaneously resulting in potent, broad immunity, and provide a quick, cheap, and reliable method to test vaccine candidates.
Original languageEnglish
Article numbere12412
JournalJournal of Extracellular Vesicles
Volume13
Issue number2
DOIs
Publication statusPublished - 9 Feb 2024

Bibliographical note

Research Funding:

Addenbrooke's Charitable Trust. Grant Number: 900239
NIHR Cambridge Biomedical Research Centre
Evelyn Trust. Grant Number: 20/40
Medical Research Foundation. Grant Number: MRF-057-0002-RG-THAV-C0798
Royal Society. Grant Number: 216370/Z/19/Z
UK Coronavirus Immunology Consortium. Grant Number: MR/V028448/1
Wellcome Trust. Grant Numbers: 204845/Z/16/Z, 216370/Z/19/Z
Blood Cancer UK. Grant Number: 20009
Medical Research Council. Grant Numbers: MC_UU_00025/12, MR/T032413/1
NHS Blood and Transplant. Grant Number: WPA15-02

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • immune presentation
  • antigen
  • SARS‐CoV‐2
  • vaccine
  • extracellular vesicles

Fingerprint

Dive into the research topics of 'Bioengineered small extracellular vesicles deliver multiple SARS‐CoV‐2 antigenic fragments and drive a broad immunological response'. Together they form a unique fingerprint.

Cite this